Ignite Creation Date:
2024-05-06 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05733689
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-02-28
First Post:
2023-02-08
Brief Title:
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers RANT-GC Trial
Sponsor:
University of California Irvine
Organization:
University of California Irvine
Study Overview
Official Title:
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers RANT-GC Trial - a Phase Ib Feasibility Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 1b prospective single arm open-label trial determining the efficacy and feasibility of using a ctDNA assay test result to help guide neoadjuvant chemotherapy in subjects with Stage IB II or Stage III adenocarcinoma of the stomach or gastroesophageal junction GEA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
True
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UCI 21-191 | OTHER | CFCCC | None |